Separation anxiety in dogs: fluoxetine plus behaviour management vs behaviour management alone — MAYBE (weak evidence)

In dogs with separation anxiety, does fluoxetine plus a behaviour management plan vs a behaviour management plan alone improve anxiety signs?

Shelf #299 · gate-verified and displayed under the developer's blinded-trial rule

MAYBE (weak evidence): The PubMed record for Simpson 2007 is indexed as a Multicenter Study and a Randomized Controlled Trial, with the MeSH term Double-Blind Method, and its abstract concludes that Reconcile (fluoxetine, 1 to 2 mg/kg/day) in conjunction with behavior management demonstrated clinical efficacy and safety for canine separation anxiety. But the abstract reports no sample size, does not name the comparator given to the control dogs, does not say who scored the outcomes, and gives no numeric result of any kind — so no effect size can be verified from the record, and on the record alone the stamp cannot rise above MAYBE (weak evidence). That is a statement about what the record shows, not a finding that fluoxetine does not work: the underlying trial may be stronger than its abstract, but VetMed cards only what the fetched record establishes. Drafted Nov 10, 2026 (VetMed build, topic #299); all figures from abstracts fetched and verified at drafting.

Simpson 2007: blinded randomised trial concluded fluoxetine chewable plus behavior management was efficacious and safe — its abstract reports no figures

Randomized Controlled Trial (publication type) with Double-Blind Method (MeSH) — multicenter study

Who: Dogs: dogs with canine separation anxiety in a multicenter study (the record's geographic MeSH terms are Canada and United States). The abstract gives no sample size, no breed or setting detail beyond the multicenter design, and does not state who scored the dogs' behaviour or whether scorers were the owners — the only blinding evidence in the record is the MeSH term Double-Blind Method (see watchOut).

Result: The abstract states, in full, that the results demonstrate the clinical efficacy and safety of Reconcile (fluoxetine, 1 to 2 mg/kg/day [0.45 to 0.91 mg/lb/day]), in conjunction with behavior management, for the treatment of canine separation anxiety, and that the beef flavored chewable formulation was palatable to treated dogs and easy to administer. No response rates, score changes, P values, adverse-event counts, or comparator results are reported in the abstract, and none are carded here.

Watch out: Design words rest on indexing, not on the abstract text: the abstract itself never uses the words randomised, blinded, or placebo and never names the control treatment, so this pack does not describe the comparator as placebo on the record's authority, even though the assigned topic framed it that way. A conclusion sentence without any verifiable figure is the weakest form of trial evidence a record can carry — which is exactly what the MAYBE (weak evidence) stamp records.

Simpson BS, Landsberg GM, Reisner IR, Ciribassi JJ, Horwitz D, Houpt KA, Kroll TL, Luescher A, Moffat KS, Douglass G, Robertson-Plouch C, Veenhuizen MF, Zimmerman A, Clark TP. Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety. Vet Ther. 2007;8(1):18-31. PMID: 17447222. Registry ID: none in the record. MeSH: Administration, Oral · Animals · Antidepressive Agents, Second-Generation · Anxiety, Separation · Behavior, Animal · Canada · Dog Diseases · Dogs · Double-Blind Method · Fluoxetine · Human-Animal Bond · Humans · Selective Serotonin Reuptake Inhibitors · Treatment Outcome · United States

Synthesis: a blinded licensure trial exists, but its PubMed record carries no verifiable result

Synthesis

Who: Synthesis of the card above: Simpson 2007 (multicenter study indexed as a Randomized Controlled Trial with MeSH Double-Blind Method; sample size not in the record).

Result: What the record establishes is that a multicenter, indexed-as-randomised-and-double-blind trial of fluoxetine chewable tablets plus behavior management was done and its authors concluded efficacy and safety at 1 to 2 mg/kg/day. What it does not establish — anywhere in the abstract — is how many dogs were studied, what they were compared against, who judged improvement, or how large any benefit was. Until a record with figures is carded, MAYBE (weak evidence) is the honest stamp for this shelf, held down by reporting, not by a negative result.

Watch out: Do not fill the gap from the neighbouring clomipramine shelf (#300): a different drug's blinded placebo-controlled result cannot be borrowed as fluoxetine's effect size.

Synthesis of Simpson BS et al. PMID: 17447222. Registry ID as on the individual card.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.